MDxHealth SA Ordinary Shares (MDXH)

FairStock Score: 19/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, have durable advantages, and sell at a discount to intrinsic value. MDxHealth is a commercial-stage precision diagnostics company with tests for prostate cancer and urinary tract infections. Revenue is growing: the data show 16.31% growth, and in the second quarter of fiscal 2026 it recorded $27.2M of revenue. But it also recorded a net loss of $11.5M in that quarter, a -42.38% margin. That is not a profitable enterprise. The balance-sheet and cash-flow signs are weak. Trailing free cash flow is -$6.0M, a -5.3% FCF yield against a $113.8M market cap. The provided ROE is -2440.41%, ROCE -9.83%, and Altman Z-score -3.94, which points to financial distress. Piotroski is 4/9. The P/E is negative at -0.94, so there is no earnings-based valuation. Price at $0.66 on 2026-10-13 is down sharply from the 52-week high of $5.33. A low price alone is not value; Graham wanted a margin of safety in assets, earnings, or cash. Here I see none clearly. Diagnostics can be a decent business if tests gain adoption and reimbursement, but the figures do not show a moat. Profit growth of -56.43% is moving the wrong way. The company may be growing revenue while destroying shareholder value. Without positive earnings or free cash flow, intrinsic value is hard to calculate. It could be an option on future test adoption, but not a conservative value investment by the numbers given.

In plain English: MDxHealth sells lab tests for prostate and urinary conditions. The business looks weak because it is losing money and using cash, even though sales are growing. At $0.66 a share, the price does not look clearly cheap against those numbers; it looks like a speculative bet on future growth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer